Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy.

Next Previous
Trial Profile

A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Valsartan (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 07 Nov 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
  • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 23 May 2011 This trial is completed in Latvia and Lithuania.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top